|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The Wayne, Pennsylvania-based company said it had a loss of 93 cents per share. Losses, adjusted for one-time gains and costs, were 75 cents per share. The pain medicine maker posted revenue of $8.2 million ...
-- Highest quarterly revenue for SPRIX Nasal Spray and OXAYDO -- WAYNE, Pa. , Nov. 19, 2018 /PRNewswire/ -- Egalet Corporation (Nasdaq: EGLT) ("Egalet"), a fully integrated specialty pharmaceutical ...
Egalet (EGLTQ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
On October 31, 2018 Egalet Corp (EGLT) announced that it has signed a purchase agreement to acquire several pain products from Iroko Pharmaceuticals, Inc. (private). With insufficient cash to satisfy the outstanding debt, Egalet entered into forbearance with noteholders leading to the Chapter 11 filing. If the proposed asset purchase agreement is approved, Egalet will acquire several assets from Iroko, including Vivlodex, Tivorbex, Zorvolex, Indocin and an in-development NSAID.
WAYNE, Pa., Oct. 31, 2018 /PRNewswire/ -- Egalet Corporation (EGLT) ("Egalet"), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative treatments for pain, today entered into an asset purchase agreement to acquire four marketed products from Iroko Pharmaceuticals, Inc. (Iroko). If consummated, the proposed transaction will enable Egalet to focus on marketing predominantly non-narcotic pain products. To facilitate this transaction and reorganize Egalet's capital structure, Egalet has initiated proceedings under Chapter 11 of the United States Bankruptcy Code in the District of Delaware.
Egalet Corporation (EGLT) released second quarter 2018 results on August 8 and filed form 10-Q on August 9 posting revenues of $7.4 million and a net loss of ($0.22) per share. The company continues to develop partnerships and add products to preferred formulary positions adding several new PBMs and plans to its portfolio. Second quarter revenues of $7.4 million were comprised of Sprix sales of $5.4 million, Oxaydo sales of $1.7 million and Arymo sales of $0.4 million.
NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Egalet Corporation (NASDAQ: EGLT ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 8:30:00 AM Eastern Time. ...
The Wayne, Pennsylvania-based company said it had a loss of 22 cents per share. Losses, adjusted for non-recurring costs, were 17 cents per share. The pain medicine maker posted revenue of $7.4 million ...
--Improvements in formulary status for key products-- --Company to host conference call today at 8:30 AM EDT-- WAYNE, Pa. , Aug. 8, 2018 /PRNewswire/ -- Egalet Corporation (Nasdaq: EGLT) ("Egalet"), ...
On Wednesday, Egalet (NASDAQ: EGLT ) will release its latest earnings report. Check out Benzinga's report to understand the earnings report's implications. Earnings and Revenue Egalet EPS will likely ...
WAYNE, Penn., July 25, 2018 /PRNewswire/ -- Egalet Corporation (EGLT) ("Egalet"), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative treatments for pain and other conditions, today announced that its second quarter 2018 financial results will be released on Wednesday, August 8, 2018. Interested parties may listen to the call via a live audio webcast which may be accessed by visiting Egalet's website. Egalet, a fully integrated specialty pharmaceutical company, is focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions.